Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Novartis To Add Warning On Blood Pressure Drug Rasilez On CHMP Recommendation

RELATED NEWS
Trade NVS now with 

Novartis AG (NVS: Quote) Friday reported the conclusion of a risk-benefit review of its high blood pressure drug Rasilez by the European Medicines Agency's, or EMA's, Committee for Medicinal Products for Human Use, or CHMP. The Committee recommended that the product information for Rasilez in the EU should warn against use by patients who are also taking an ACE inhibitor or an ARB.

The review, which followed Novartis's decision to terminate its ALTITUDE study in the wake of a high incidence of adverse events, found that patients who have diabetes or mild-to-moderate renal impairment should consult a physician before using a combination product containing aliskiren, for which Rasilez is the trade name. The update also applies to other aliskiren products such as Sprimeo, Riprazo and Rasilamlo.

Click here to receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Hewlett-Packard has recalled the AC power cords for its HP and Compaq notebook computer, citing a tendency to overheat, causing a potential fire and burn hazard. HP requests that consumers stop using the cord immediately and contact them to order a replacement cord free of charge. A UN report describing terrible atrocities carried out by Islamic State militants in Syria says children as young as 10 are being recruited and trained at ISIS camps as fighters. The report, based on 480 interviews and and evidence collected between 20 January and 15 July, chronicles the unimaginable brutality and human cost of the Syrian conflict. The report by the independent international com Poverty in Latin America and the Caribbean has been reduced by almost half in the last decade, and the middle class grew by 82 million people, from 21 percent of the population in 2000 to 34 percent in 2012, according to new data released by the United Nations Development Program (UNDP). UNDP's analysis, based on data from the Center for Distributive, Labor and Social Studies (CEDLAS), highlights
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.